Clario Announces Sale of Software Solutions Business to Sitero
PHILADELPHIA, PA – August 1, 2023 – Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced the sale of its Software Solutions business, an end-to-end solution to support the clinical trial lifecycle.
The Clario eClinical product suite (including CTMS, eConsent, EDC, RTSM / IRT, Patient and Site Payments) will be rebranded and integrated into the established Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing innovative Clinical solutions for new customers as well.
The sale underlies Clario’s continuing commitment to focusing on clinical evidence generation backed by deep scientific expertise across its eCOA, Cardiac Safety, Respiratory and Medical Imaging business lines. Underpinning this commitment is Clario’s continued investments in new technologies (including AI/ML), endpoint data collection, and generating the richest and highest quality data for our customers.
Commenting on the sale, Chris Fikry, CEO of Clario, said, “Our clinical trial solutions business provides important support and services for our sponsors looking for an end-to-end solution for their clinical trial. Following a strategic review of the business, Clario determined the best path forward for this business was its sale to Sitero. Sitero is well-prepared to provide the strong strategic support the business needs to grow, and Clario looks forward to maintaining a partnership with the business going forward. ”
Clario was advised by Cain Brothers, a division of KeyBanc Capital Markets on the transaction.
About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.
For more information, go to Clario.com or follow us on LinkedIn.
Media Contact:
David Malley
Director of Brand, Content Strategy, and Communications
[email protected]